Cencora reported Q1 fiscal year revenue of $85.93 billion, slightly missing Wall Street estimates of $86.03 billion, but beat earnings expectations with adjusted EPS of $4.08 versus consensus of $4.03. The company raised its 2026 sales growth guidance from 5%-7% to 7%-9% and increased full-year sales guidance to $343.79-$350.22 billion. However, the stock declined 6.67% following the announcement.

The global comparator drug sourcing market is projected to grow from USD 1.42 billion in 2025 to USD 2.72 billion by 2033, at a CAGR of 8.47%. Growth is driven by increasing global clinical trials, rising complexity of biologics, and growing outsourcing trends. North America leads with 44.60% market share, while Asia-Pacific is the fastest-growing region at 9.03% CAGR. Central sourcing dominates with 55.60% market share, while contract manufacturing organizations are the fastest-growing application segment.

AOP Health US announced expanded distribution of Rapiblyk™ (landiolol), an FDA-approved ultra-short-acting beta-blocker for treating rapid heart rates in critical care settings. The drug is now available through four major pharmaceutical wholesalers: Cardinal, Cencora Specialty Distribution, McKesson Corporation, and Morris & Dickson, enhancing accessibility for hospitals and health systems nationwide.

Cencora agreed to acquire a majority stake in OneOncology for $5 billion, funded through new debt financing. The transaction is expected to close by the end of fiscal 2026 second quarter and is anticipated to be earnings neutral in the first twelve months.

Iterum Therapeutics reports expanding market access for ORLYNVAH™, securing nearly 25% insurance coverage in the U.S. and signing a Medicare Part D rebate agreement with a top Pharmacy Benefit Manager, with potential coverage starting in Q1 2026.

Cencora reported strong Q3 financial results with sales increasing 8.7% to $80.66 billion, driven by growth in healthcare solutions and GLP-1 class product sales. The company raised its full-year adjusted EPS guidance and expects continued revenue growth.

The global cell and gene therapy third-party logistics market is projected to grow from $8.66 billion in 2024 to $20.98 billion by 2033, driven by technological advancements, increasing clinical studies, and personalized medicine demands.

The healthcare cold chain logistics market is projected to surpass $25 billion by 2025, driven by the increasing demand for specialized logistics solutions due to the complexity of distribution networks for biological therapies. However, the high costs associated with cold storage and transportation present challenges for the industry.

Cencora, a healthcare company, reported strong Q4 2024 earnings and announced the acquisition of Retina Consultants of America for $4.6 billion. The deal will add nearly 300 retina specialists to Cencora's portfolio, and the company also increased its dividend.

Datapro Inc., a leader in financial services technology, has announced a comprehensive brand refresh and the launch of a redesigned website. The changes are aimed at better reflecting the company's commitment to innovation, agility, and forward-thinking solutions.

The three largest U.S. drug distributors, McKesson, Cencora, and Cardinal Health, have agreed to pay $300 million to resolve claims from health insurers and benefit plans over their alleged role in the opioid epidemic. The settlement comes on the heels of a $21 billion agreement by the same companies to settle claims from state and local governments.

Walgreens is facing cash flow issues, with negative operating cash flow in recent quarters and high current liabilities compared to current assets. The company has had to sell its stake in Cencora to raise cash, and its dividend cut earlier this year may not be enough to address the underlying problems.